x
Breaking News
More () »

CBS News 8 - San Diego, CA News Station - KFMB Channel 8 | cbs8.com

Official: Merck to help produce rival Johnson & Johnson's COVID-19 vaccine

The announcement comes as the White House looks to speed the production of the single-dose vaccine.

WASHINGTON — Drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved coronavirus vaccine in an effort to expand supply more quickly, a Biden administration official confirmed Tuesday.

The announcement comes as the White House looks to speed the production of the single-dose vaccine. Officials have said J&J faced unexpected production issues with its vaccine and produced only 3.9 million doses ahead of its receiving emergency use authorization on Saturday. The company says it is on pace to deliver 100 million doses by the end of June.

Facing questions about the company's slipping delivery schedule, J&J Vice President Richard Nettles told lawmakers on Capitol Hill last week that the company had faced “significant challenges” because of its “highly complex” manufacturing process.

The assistance from Merck was expected to help J&J meet its production commitments and expand supply even further, but the administration did not immediately provide specifics.

RELATED: US panel endorses 3rd vaccine option, from Johnson & Johnson

RELATED: Fauci encourages Americans to take the vaccine 'most available to them'

President Joe Biden is set to highlight the development in a speech Tuesday afternoon, as his administration now expects to have enough supply of the three approved vaccines to inoculate all eligible American adults by June — though actually delivering the injections could take longer.

The official confirmed Merck’s involvement on condition of anonymity ahead of Biden’s public announcement. The news was first reported by The Washington Post.

It was not immediately clear when the effect of Merck's assistance would be reflected in supply. Previously, federal officials have cautioned that setting up the highly specialized manufacturing lines to produce vaccines would take months.

Merck halted its own plans to develop a coronavirus vaccine earlier this year, finding that their candidates were generating an inferior immune system response compared with other vaccines. It said it would instead focus its work on developing treatments for COVID-19.

Compared to the two-dose versions produced by Moderna and Pfizer, the J&J vaccine is less resource intensive to distribute and administer, making it a critical piece to U.S. plans to spread vaccinations around the world — but only once Americans are inoculated. The J&J vaccine can be stored for months at refrigerated temperatures, rather than frozen, and doesn't require patients to return for a second dose three or four weeks later.

Credit: AP
FILE - This Dec. 2, 2020, file photo provided by Johnson & Johnson shows vials of the COVID-19 vaccine in the United States. (Johnson & Johnson via AP)

For most people, the coronavirus causes mild or moderate symptoms. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia and death.

The United States has more than 28 million confirmed cases of COVID-19, according to data from Johns Hopkins University.

As of Tuesday, the U.S. had more than 514,000 deaths from the virus. Worldwide, there are more than 114 million confirmed cases with more than 2.5 million deaths.

RELATED: Comparing Pfizer, Moderna and J&J shots isn't an apples-to-apples comparison

RELATED: 20 million Americans have gotten both COVID vaccine doses

RELATED: US has 'lowest flu season' on record during COVID pandemic